Therapeutic targeting of ligands by CTLA4-Ig fusion proteins (Abatacept) or blocking CTLA4 with antibodies (e.g. Ipilimumab) have been used in autoimmunity and cancer to inhibit or invigorate CD28 signals, respectively. This evidence concerns the gene CD28 and cancer.